Drug Trial Radar · NCT04077580
The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI
Last checked: Nov 19, 2026Latest source record: Sep 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
289
Actual
Start
Nov 1, 2019
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- University of OsloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amsterdam UMC, location VUmc; UMC Utrecht; Göteborg University; Medical University of Lodz
- First posted
- Sep 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 70 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recurrent urinary tract infection (UTI) in elderly women is a major driver of antibiotic prescription. Hence, the question of feasible and appropriate preventive measures are important issues in this field. Methenamine hippurate is frequently prescribed in Norway and Sweden as prophylaxis for recurrent UTI. Methenamine hippurate acts via the production of formaldehyde from hexamine, which in turn acts as a bacteriostatic agent, therefore methenamine hippurate is not defined as an antibiotic. According to a Cochrane review 2012 the rates of adverse events for preventing UTI was low. Although this review showed methenamine hippurate might be effective in preventing UTI in the short term, there is a need for large well-conducted randomised controlled trial (RCT) to clarify both the safety and effectivity of preventive methenamine hippurate for longer term use. This is particularly important for longer term use for people without neuropathic bladder disorders. A Norwegian longitudinal observational study including women aged 50-80 years with recurrent UTI indicated a significant and large reduction of more than 50% in antibiotic prescriptions for UTI after start of prophylactic methenamine hippurate. This further strengthens the need for an RCT of methenamine hippurate as prophylaxis for recurrent UTI.
Conditions
- Recurrent Urinary Tract Infection
Interventions
Methenamine Hippurate 1000 MGDrug
Methenamine and placebo is taken 1 tablet morning and evening for 180 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective of this study is to investigate if taking methenamine hippurate reduces the need for antibiotic usage due to recurrent UTI (measured as number of antibiotic courses).Time frame: 6 months
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
University of Oslo
Oslo, Norway
Medical University of Lodz,
Lodz, Poland
Research and Development Primary Health Care, Region Västra Götaland,
Borås, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.